{
    "Trade/Device Name(s)": [
        "Access Myoglobin"
    ],
    "Submitter Information": "Beckman Coulter, Inc.",
    "510(k) Number": "K231832",
    "Predicate Device Reference 510(k) Number(s)": [
        "K021229"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "DDR"
    ],
    "Summary Letter Date": "June 21, 2023",
    "Summary Letter Received Date": "June 22, 2023",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5680"
    ],
    "Regulation Name(s)": [
        "Myoglobin Immunological Test System"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Myoglobin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [
        "Heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "DxI 9000 Access Immunoassay Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Chemiluminescent immunoassay",
        "Immunoenzymatic assay"
    ],
    "Methodologies": [
        "Sandwich immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent",
        "Calibrator",
        "Substrate",
        "Buffer"
    ],
    "Document Summary": "FDA 510(k) summary for Access Myoglobin chemiluminescent immunoassay on DxI 9000 Access Immunoassay Analyzer for quantitative determination of myoglobin",
    "Indications for Use Summary": "Quantitative determination of myoglobin in human serum and plasma to aid in diagnosis of heart or renal disease using Access Immunoassay Systems",
    "fda_folder": "Immunology"
}